[HTML][HTML] Synaptic vesicle glycoprotein 2 A in serum is an ideal biomarker for early diagnosis of Alzheimer's disease
X Wang, X Zhang, J Liu, J Zhang, C Liu, Y Cui… - Alzheimer's Research & …, 2024 - Springer
Background Previous studies have demonstrated that early intervention was the best plan to
inhibit the progression of Alzheimer's disease (AD), which relied on the discovery of early …
inhibit the progression of Alzheimer's disease (AD), which relied on the discovery of early …
[引用][C] O2‐05‐01: CEREBROSPINAL FLUID SYNAPTIC VESICLE GLYCOPROTEIN 2A IN ALZHEIMER'S DISEASE
NJ Ashton, K Höglund, A Leuzy… - Alzheimer's & …, 2019 - Wiley Online Library
Background Measuring synaptic density in vivo with positron emission tomography targeting
synaptic vesicle protein 2A (SV2A) has received much attention recently due to varied …
synaptic vesicle protein 2A (SV2A) has received much attention recently due to varied …
Synaptic vesicle glycoprotein 2A (SV2A) levels in the cerebral cortex in patients with Alzheimer's disease: a radioligand binding study in postmortem brains
JD Mikkelsen, S Kaad, SS Aripaka, B Finsen - Neurobiology of Aging, 2023 - Elsevier
Histological and biochemical analyses in postmortem tissues have demonstrated
neurodegenerative changes in the cerebral cortex in patients with Alzheimer's disease (AD) …
neurodegenerative changes in the cerebral cortex in patients with Alzheimer's disease (AD) …
[HTML][HTML] Increased inflammation and unchanged density of synaptic vesicle glycoprotein 2A (SV2A) in the postmortem frontal cortex of Alzheimer's disease patients
A Metaxas, C Thygesen, SRR Briting… - Frontiers in cellular …, 2019 - frontiersin.org
Sections from the middle frontal gyrus (Brodmann area 46) of autopsy-confirmed Alzheimer's
disease (AD) patients and non-demented subjects were examined for the prevalence of …
disease (AD) patients and non-demented subjects were examined for the prevalence of …
[HTML][HTML] Evaluation of cerebrospinal fluid levels of synaptic vesicle protein, VAMP-2, across the sporadic Alzheimer's disease continuum
J Goossens, A Cervantes González, N Dewit… - Alzheimer's Research & …, 2023 - Springer
Background Synapse loss is an early event that precedes neuronal death and symptom
onset and is considered the best neuropathological correlate of cognitive decline in …
onset and is considered the best neuropathological correlate of cognitive decline in …
[HTML][HTML] The synaptic vesicle protein 2A interacts with key pathogenic factors in Alzheimer's disease: implications for treatment
Y Kong, L Huang, W Li, X Liu, Y Zhou, C Liu… - Frontiers in cell and …, 2021 - frontiersin.org
Alzheimer's disease (AD), a serious neurodegenerative disease, is pathologically
characterized by synaptic loss and dysfunction. Synaptic vesicle protein 2A (SV2A) is an …
characterized by synaptic loss and dysfunction. Synaptic vesicle protein 2A (SV2A) is an …
[HTML][HTML] Cerebrospinal fluid synaptosomal-associated protein 25 is a key player in synaptic degeneration in mild cognitive impairment and Alzheimer's disease
H Zhang, J Therriault, MS Kang, KP Ng… - Alzheimer's research & …, 2018 - Springer
Background There is accumulating evidence that synaptic loss precedes neuronal loss and
correlates best with impaired memory formation in Alzheimer's disease (AD). Cerebrospinal …
correlates best with impaired memory formation in Alzheimer's disease (AD). Cerebrospinal …
Pro-inflammatory S100A9 protein as a robust biomarker differentiating early stages of cognitive impairment in Alzheimer's disease
Pro-inflammatory protein S100A9 was established as a biomarker of dementia progression
and compared with others such as Aβ1–42 and tau-proteins. CSF samples from 104 …
and compared with others such as Aβ1–42 and tau-proteins. CSF samples from 104 …
[HTML][HTML] Decreased synaptic vesicle glycoprotein 2A binding in a rodent model of familial Alzheimer's disease detected by [18F]SDM-16
C Zheng, T Toyonaga, B Chen, LS Nicholson… - Frontiers in …, 2023 - frontiersin.org
Introduction Synapse loss is one of the hallmarks of Alzheimer's disease (AD) and is
associated with cognitive decline. In this study, we tested [18F] SDM-16, a novel …
associated with cognitive decline. In this study, we tested [18F] SDM-16, a novel …
Cerebrospinal Fluid Synaptosomal-Associated Protein 25 Levels in Patients with Alzheimer's Disease: A Meta-Analysis
Q Liu, H Liu, S Zhang, Q Yang… - Journal of Alzheimer's …, 2022 - content.iospress.com
Background: Several studies have shown increased levels of cerebrospinal fluid (CSF)
synaptosomal-associated protein 25 (SNAP-25) in patients with Alzheimer's disease (AD) …
synaptosomal-associated protein 25 (SNAP-25) in patients with Alzheimer's disease (AD) …
相关搜索
- alzheimer's disease vesicle glycoprotein
- early diagnosis ideal biomarker
- vamp 2 vesicle protein
- alzheimer's disease synaptic biomarkers
- alzheimer's disease early diagnosis
- fluid levels vesicle protein
- frontotemporal dementia synaptic biomarkers
- unchanged density vesicle glycoprotein
- fluid associate synaptic biomarkers
- robust biomarker s100a9 protein
- postmortem brains vesicle glycoprotein
- increased inflammation vesicle glycoprotein
- implications for treatment vesicle protein
- cerebral cortex vesicle glycoprotein
- early stages s100a9 protein
- robust biomarker early stages